REG - CVS Group plc - Exercise of Options and Total Voting Rights

CVSAnnouncement

31/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240131:nRSe4312Ba&default-theme=true

RNS Number : 4312B  CVS Group plc  31 January 2024

31 January 2024

CVS Group plc

("CVS" or the "Company")

Exercise of Options and Total Voting Rights

CVS, one of the UK's leading providers of integrated veterinary services,
confirms that certain employees have exercised options during January under
the CVS Group 2020 SAYE Plan (2020/2024) totalling 211,401 ordinary shares of
0.2 pence each ("Ordinary Shares"). One employee also exercised options under
the CVS Group Long Term Incentive Plan 2020 ("LTIP 14") over 6,733 new
Ordinary Shares.

The issuance of shares in connection with the SAYE Exercise was partially
satisfied by 47,300 Ordinary Shares held by the CVS Group Employee Benefit
Trust (the "EBT").  Additionally, the issuance of shares in connection with
the LTIP 14 Exercise was fully satisfied by 6,733 Ordinary Shares held by the
EBT. Following the SAYE and LTIP 14 Exercise, a total of 645 Ordinary Shares
are held by the EBT, representing approximately 0.001% of the Company's total
voting rights.

The sum of 164,101 new Ordinary Shares were issued to partially satisfy the
balance of Ordinary Shares arising from the SAYE Exercise.  Admission of the
164,101 new Ordinary Shares has been satisfied by the Company's block listing
admitted to the London Stock Exchange on 30 December 2021.

Following the issue of these new Ordinary Shares, which rank pari passu in all
respects with the Company's existing Ordinary Shares, the Company has a total
issued share capital of 71,701,763 Ordinary Shares, each carrying one voting
right. The Company holds no Ordinary Shares in treasury and the total number
of voting rights is therefore 71,701,763.

This figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest, or a change to their interest, in the Company under the FCA's
Disclosure Guidance and Transparency Rules.

Contacts:

CVS Group
plc
via Camarco

Richard Fairman, CEO

Scott Morrison, Company Secretary

 

Peel Hunt LLP (Nominated Adviser &
Broker)
+44 (0)20 7418 8900

Adrian Trimmings / Michael Burke / Andrew Clark / Lalit Bose

 

   Berenberg (Joint
Broker)
+44 (0)20 3207 7800

Toby Flaux / Ben Wright / Ciaran Walsh / Milo Bonser

 

Camarco (Financial
PR)

Geoffrey
Pelham-Lane
                     +44 (0)7733 124 226

Ginny
Pulbrook
+44 (0)7961 315 138

 

About CVS Group plc (www.cvsukltd.co.uk (http://www.cvsukltd.co.uk/) )

CVS Group is an AIM-listed provider of veterinary services in the UK,
Australia, the Netherlands and the Republic of Ireland.  CVS is focused on
providing high quality clinical services to its clients and their animals,
with outstanding and dedicated clinical teams and support colleagues at the
core of its strategy.

 

The Group has c.500 veterinary practices across its four markets, including
nine specialist referral hospitals and 39 dedicated out-of-hours sites.
Alongside the core Veterinary Practices division, CVS operates Laboratories
(providing diagnostic services to CVS and third-parties), Crematoria
(providing pet cremation and clinical waste disposal for CVS and third-party
practices), Buying Groups and the Group's online retail business ("Animed
Direct").

 

The Group employs c.9,000 personnel, including c.2,400 veterinary surgeons and
c.3,300 nurses.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRBRGDBXXXDGSG